WebFulphila is not indicated for the mobilization of peripheral blood progenitor cells for hematopoietic stem cell transplantation. IMPORTANT SAFETY INFORMATION. ... Fulphila ® (pegfilgrastim-jmdb) injection. Prescribing Information. 2024. Mylan Pharmaceuticals … Do not administer Fulphila to patients with a history of serious allergic reactions, … Randomized, double-blind, parallel-group trial evaluating equivalence of … If causality is likely, consider dose-reduction or interruption of Fulphila. White blood … Do not administer Fulphila to patients with a history of serious allergic reactions, … If causality is likely, consider dose-reduction or interruption of Fulphila. White blood … Indication. Fulphila ® is indicated to decrease the incidence of infection, as … WebJun 13, 2005 · Star. Summary. Pegfilgrastim is a recombinant human granulocyte colony stimulating factor used to stimulate the production of neutrophils and prevent febrile neutropenia or infections after myelosuppressive chemotherapy. Brand Names. Fulphila, Fylnetra, Neulasta, Udenyca, Ziextenzo. Generic Name. Pegfilgrastim.
Fulphila® (pegfilgrastim-jmdb) Efficacy HCPs
WebFeb 10, 2024 · Allow prefilled syringe to reach room temperature for ≥30 minutes prior to injection; discard if kept at room temperature for>48 hours (Neulasta, Udenyca) or 72 hours (Fulphila, Ziextenzo). The On-body injector kit (Neulasta) should be kept refrigerated until 30 minutes prior to use and should not be held at room temperature for >12 hours ... WebOct 15, 2024 · Patients with Cancer Receiving Myelosuppressive Chemotherapy. The recommended dosage of Fulphila is a single subcutaneous injection of 6 mg administered once per chemotherapy … otd dayton wheels
Fulphila (Mylan Institutional LLC): FDA Package Insert
WebJun 2, 2024 · Our Fulphila (pegfilgrastim-jmdb) Injection Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication. This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. WebIf causality is likely, consider dose-reduction or interruption of Fulphila. White blood cell counts of 100 x 10 9 /L or greater have been observed in patients receiving pegfilgrastim products. Monitoring of CBCs during therapy with Fulphila is recommended. Thrombocytopenia has been reported in patients receiving pegfilgrastim. Monitor … WebOct 1, 2015 · FULPHILA™ (pegfilgrastim-jmdb) injection, for subcutaneous use Initial U.S. Approval: 2024 Holmes, F., O’Shaughnessy, S., Vukelja, S., et al. (2002). Blinded, … otd death